11 September 2026 in Clinical Infectious Diseases
Background: At hospice enrollment, patients are asked for preferences regarding antibiotic use. Limited evidence on how these medications impact survival makes it difficult for clinicians to offer clear guidance. To support decision making and antimicrobial stewardship, we assessed the association between antibiotic use and survival in outpatient hospice patients. Methods: The association between antibiotic use and survival was evaluated using a time-dependent Cox proportional hazards model, adjusted for age, sex, Charlson Comorbidity Index, and hospice-qualifying conditions (HQCs). The cohort included patients enrolled in a large health system's outpatient hospice program between 20 June 2017 and 1 January 2023. Results: Among 6169 patients with an HQC, 1233 received at least 1 antimicrobial prescription during the study period. The median time from hospice enrollment to first prescription was 16 days (interquartile range [IQR] 3–83). Antimicrobial prescribing patterns varied by HQC category. In time-dependent Cox models, antibiotic use was associated with increased hazard of death (adjusted hazard ratio [aHR] 1.47; 95% confidence interval [CI], 1.37–1.57).Stratified analyses showed the strongest association with increased mortality in patients with cancer HQCs (aHR 1.67; 95% CI, 1.50–1.87) and a survival benefit in those with infectious HQCs (aHR 0.60; 95% CI, .40–.89). Conclusions: Physicians, patients, and families often overestimate the benefits of antibiotics near the end of life. The observed increase in mortality shortly after antibiotic initiation suggests that symptoms prompting antibiotic use may reflect the dying process rather than treatable infection. Knowledge of the limited role of antibiotics in prolonging life in hospice settings may improve decision-making and enhance the quality of end-of-life care.
30 October 2026 in Clinical Infectious Diseases